{"filing":{"accession_number":"0001178913-26-004786","cik":"0001553846","ticker":"RDHL","company_name":"RedHill Biopharma Ltd.","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"zk2636236.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553846/000117891326004786/zk2636236.htm"},"events":[{"id":35960,"run_id":33149,"accession_number":"0001178913-26-004786","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"RedHill announced that its partner University of Oklahoma received a $2.9 million National Cancer Institute grant to fund clinical trials (Phase 1b and Phase 2) evaluating opaganib in combination with CAR T-cell therapy for ultra-high-risk multiple myeloma. This is a material operational and strategic milestone—a significant government-backed research collaboration that advances the clinical development of a key pipeline asset (opaganib) and demonstrates external validation of the company's therapeutic approach. While not a discrete M\u0026A transaction, debt issuance, or earnings event, it represents a material operational development that would affect a reasonable investor's assessment of RedHill's pipeline progress and partnerships.","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40200,"accession_number":"0001178913-26-004786","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"RedHill announced that its partner University of Oklahoma received a $2.9 million National Cancer Institute grant to fund clinical trials (Phase 1b and Phase 2) evaluating opaganib in combination with CAR T-cell therapy for ultra-high-risk multiple myeloma. This is a material operational and strategic milestone—a significant government-backed research collaboration that advances the clinical development of a key pipeline asset (opaganib) and demonstrates external validation of the company's therapeutic approach. While not a discrete M\u0026A transaction, debt issuance, or earnings event, it represents a material operational development that would affect a reasonable investor's assessment of RedHill's pipeline progress and partnerships.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:03:49.349715+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40200,"accession_number":"0001178913-26-004786","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"RedHill announced that its partner University of Oklahoma received a $2.9 million National Cancer Institute grant to fund clinical trials (Phase 1b and Phase 2) evaluating opaganib in combination with CAR T-cell therapy for ultra-high-risk multiple myeloma. This is a material operational and strategic milestone—a significant government-backed research collaboration that advances the clinical development of a key pipeline asset (opaganib) and demonstrates external validation of the company's therapeutic approach. While not a discrete M\u0026A transaction, debt issuance, or earnings event, it represents a material operational development that would affect a reasonable investor's assessment of RedHill's pipeline progress and partnerships.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:03:49.349715+00:00","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-10-19"}]}